Research Centers (RC) to support the Centers for Research in Emerging Infectious Diseases (CREID) Network (RFA-AI-24-006)

Research Centers (RC) to support the Centers for Research in Emerging Infectious Diseases (CREID) Network (RFA-AI-24-006) is sponsored by National Institutes of Health (NIH). This notice of funding opportunity (NOFO) invites applications for Research Centers to support the CREID Network. The network expands knowledge on re-emerging and emerging infectious diseases globally.

Expired RFA-AI-24-006: Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial Not Allowed) This notice has expired. Check the NIH Guide for active opportunities and notices. Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Institute of Allergy and Infectious Diseases ( NIAID ) Funding Opportunity Title Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial Not Allowed) U01 Research Project – Cooperative Agreements April 25, 2024 - Notice of Budget Change in RFA-AI-24-006 Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial Not Allowed).

See Notice NOT-AI-24-046 August 31, 2022 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198 . August 5, 2022 - Implementation Details for the NIH Data Management and Sharing Policy.

See Notice NOT-OD-22-189 . Funding Opportunity Number (FON) Companion Funding Opportunity Research Project (Cooperative Agreements) See Section III. 3.

Additional Information on Eligibility. Assistance Listing Number(s) Funding Opportunity Purpose The purpose of this notice of funding opportunity (NOFO) is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Research Centers (RCs).

The CREID Network, comprised of all recipients under this NOFO and the companion NOFO [ RFA-AI-24-016 ] , serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research.

Multi- and interdisciplinary teams of domestic and international investigators will conduct innovative, collaborative, hypothesis-driven One Health (approach that recognizes the health of humans is interconnected with that of animal health and the shared environment) based research, will undertake outbreak-related research when necessary in their geographical areas, and will work across the CREID Network in a coordinated, collaborative, and cooperative fashion.

Open Date (Earliest Submission Date) Letter of Intent Due Date(s) 30 days prior to the application due date Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide , follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

Part 1. Overview Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.

Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII.

Agency Contacts Section VIII. Other Information Part 2. Full Text of Announcement Section I.

Notice of Funding Opportunity Description The purpose of this notice of funding opportunity (NOFO) is to invite applications for the Centers for Research in Emerging Infectious Diseases (CREID) Network Research Centers (RCs).

The CREID Network, comprised of all awards made under this NOFO and the companion NOFO [ RFA-AI-24-016 ], serves to expand knowledge on re-emerging and emerging infectious diseases (re/EIDs) around the globe where outbreaks are most likely to occur while developing expertise, capacity, and readiness to address outbreak-related research.

Multi- and interdisciplinary teams of domestic and international investigators will conduct innovative, collaborative, hypothesis-driven One Health (approach that recognizes the health of humans is interconnected with that of animal health and the shared environment) based research, will undertake outbreak-related research when necessary, in their geographical areas, and will work across the CREID Network in a coordinated, collaborative, and cooperative fashion.

Core elements of NIAID’s mission include expanding the breadth and depth of knowledge in infectious diseases and developing flexible domestic and international research capacities to respond appropriately to emerging and re-emerging disease threats domestically and internationally. Recent emergences of viral, zoonotic origin infectious pathogens have demonstrated their ability to significantly impact human health and quality of life.

As our environments and populations change, it is expected that re/EID events will increase in frequency and have significant potential to threaten global health. Many of these naturally occurring recent outbreaks have been caused by viral pathogens and characterized by their zoonotic reservoirs and/or arthropod vectors propagating transmission to humans.

In many instances, re-emerging pathogens have circulated undetected or at low levels for several years before causing significant outbreaks with major public health concerns, and novel pathogens continue to emerge with the potential to cause world-wide pandemics.

These prior outbreaks have revealed inefficiencies in communication, coordination, and collaboration between unlinked investigators or networks which made it difficult for NIAID to leverage quickly and efficiently for outbreak-related research efforts.

To address these challenges, NIAID established the Centers for Research in Emerging Infectious Diseases Network in 2020 which is currently comprised of ten Research Centers (RCs) and a single Coordination Center (CC).

The CREID Network draws on skills from teams of multidisciplinary scientists, including for example, infectious disease clinicians, epidemiologists, virologists, clinical microbiologists, veterinarians, and entomologists to conduct innovative, collaborative, and coordinated One Health based research on re/EIDs that have the greatest potential of becoming pandemic threats (such as zoonotic and vector-borne viruses).

Additionally, the multidisciplinary teams also strengthen and/or develop flexible domestic and international capacities and readiness to efficiently conduct research related to outbreaks and contribute to the development of the next generation of emerging infectious disease scientists and leaders globally.

The CREID Network will provide continued support towards the broader NIAID strategy for pandemic preparedness by expanding our knowledge of re/EIDs and strengthening research infrastructure and scientific expertise in geographical regions of the world that are prone to re/EIDs.

Research Objectives and Scope Each Research Center (RC), as part of the CREID Network, will be responsible for executing research that will expand our knowledge of re/EIDs while developing flexible domestic and international capacities, and strengthening research infrastructure and scientific expertise through development of the next generation of emerging infectious disease scientists and leaders globally.

Each RC will develop multi- or interdisciplinary One Health based hypothesis driven research for re/EIDs. Each RC must incorporate both animal and human subjects elements to fulfill their One Health research goals and objectives, and other elements such as vectors or climate/environment may be incorporated towards the One Health approach.

The human based elements of the research may include utilization of human subjects’ cohorts, either short-term (e.g., acute febrile illness, AFI) or long-term/longitudinal cohorts and use of archived clinical specimens.

Research topics that may be supported include, for example: pathogen discovery and characterization, pathogen surveillance in animals, vectors, and humans as it relates to assessment of prevalence, molecular epidemiology of specific pathogens in their geographic regions, and/or linked with another topic area listed here, evaluation of factors related to pathogen transmission, maintenance, emergence, adaptation, and evolution (including the role of climate change and/or social science elements) related to human infections, define the contemporary spectrum of clinical disease presentation and progression, pathophysiology, and clinical outcomes of infection in humans (including sequelae) and/or determinants of disease severity, human immunologic responses to the infection, development of reagents, diagnostic/detection tools, and critical animal models, and research that is foundational or translatable to, or will enable, the further development of medical countermeasures (therapeutic and preventative) to important human health re/EIDs.

Each RC may study any emerging pathogen (viral, bacterial or eukaryotic), however, the primary focus is expected to be on viral infectious pathogens that are most likely to emerge/reemerge in humans.

Applicants are required to work on at least one viral pathogen from the NIAID list of Emerging Diseases including, but not limited to, members of viral families: Arenaviridae, Coronaviridae, Flaviviridae, Filoviridae, Hantaviridae, Nairoviridae, Paramyxoviridae, Peribunyaviridae, Phenuiviridae, Picornaviridae, and Togaviridae that are not already studied by other NIAID funded networks (e.g. HIV, influenza, malaria) and for which countermeasures are not developed or are suboptimal.

Each RC may propose to work in any region of the world that is considered a hotspot (known area of high viral biodiversity and/or area with frequent occurrences of outbreaks/epidemics) for re/EIDs. Applicants are encouraged to propose working in at least two geographic regions with at least one located within the tropical or subtropical regions of the world (Tropics: latitude between 23.

5 o -Tropic of Cancer and Capricorn-Subtropics: between tropic and temperate zones (35-66. 5 o N and’s of the equator) with the goal of establishing research sites in targeted areas of the globe such as South and Central America, Sub-Saharan Africa, and Southeast Asia.

Each RC will complement and leverage existing NIAID international research efforts such as the Centers of Excellence for Influenza Research and Response (CEIRR), International Centers of Excellence for Malaria Research (ICEMR), Tropical Medicine Research Centers (TMRC), and Centers for AIDS Research (CFAR) and/or other US Government or internationally funded research infrastructure as needed to conduct the proposed research and exhibit the flexibility to pivot capacity or resources to address outbreak-related research needs in their geographic area, in consultation with NIAID.

Coordination, Collaboration, and Cooperation: Coordination, collaboration, and cooperation are key elements and priorities of the CREID Network.

Each RC will be required to coordinate, collaborate, and cooperate with the other recipient RCs, the CC, NIAID, and relevant interest holders (a person, group, or organization with a vested interest in addressing re/EIDs, examples include other USG or international agencies or programs and/or other NIAID-funded programs) to maximize resource utilization, minimize duplication of efforts, strengthen scientific domestic and international relationships and trust, identify research gaps, translate research tools or products to downstream partners, and facilitate successful implementation and achievement of the research projects and goals of the CREID Network.

To further support coordination, collaboration, and cooperation across the CREID Network, each RC will readily share information, data, specimens, diagnostics, reagents, models, tools, or any research products that arise from the award within the CREID Network, the greater scientific community, and other downstream partners or interest holders to aid in translational research or development of medical countermeasures and/or preventive interventions both before and during outbreak events.

Additional highlighted areas of coordination, collaboration, and cooperation include but are not limited to: shared or complementary topic research projects, outbreak-related research, data stewardship, scientific working groups, publications, scientific expertise development and capacity strengthening, and annual CREID Network meetings.

Each RC will participate and collaborate to help achieve interoperability amongst the CREID Network centers via processes and systems provided by the CC, for example governance structure, working groups, committees. To enable effective, global preparedness for and rapid outbreak-related research to re/EIDs threats, each RC will strengthen and build domestic and international capacities through their research and collaborations.

Each RC will define their capacity building or strengthening goals and should design their research program or incorporate elements that will allow them to develop or strengthen scientific expertise, abilities, or infrastructure towards preparedness and readiness to undertake outbreak-related research at their domestic and international research sites.

Additionally, a capacity strengthening, and pilot research program will be developed and managed by the CC and each RC may be asked to contribute expertise, mentorship, and guidance to the program as requested by the CC or in consultation with NIAID.

Each RC will develop and manage, in consultation with NIAID, an Opportunity Fund that is intended to strengthen the impact of the overall CREID Network, which may include enhancement of shared or complementary topic research within the CREID Network , preparedness and outbreak-related research and activities, and other activities or efforts that further the collaborative objectives and goals of the CREID Network .

CREID Research Center Structure Administration and Leadership Team Data Stewardship and Analysis Team The Data Stewardship and Analysis Team (RC DSAT) will be responsible for the range of activities related to data and information generated by the RC and exchanged among the CREID Network including: collection, management, distribution, analyses, quality assurance and standards, and development of statistically powered study designs for the RC.

The RC DSAT will also collaborate and cooperate with the CC and other awarded RCs to facilitate implementation of data stewardship and analysis practices provided by the CC or adopted by the CREID Network.

The RC DSAT will implement processes and procedures for receipt, storage, retrieval, and inventory of biological specimens, harmonization of specimens to clinical and experimental data (including metadata), tracking and monitoring of biological specimen use, storage, and/or distribution, and implementing of safety and security features for specimen storage and retrieval.

This exchange of information generated by award recipients (CC and RC) to the CREID Network is intended to operationalize activities for achieving the goals of the program. The RC DSAT will also be responsible for executing data sharing agreements (DSAs) for exchange of data generated under the RC awards. Additionally, and separate from the RC DSAT, recipients are required to adhere to all applicable sharing policies.

Clinical Research Support Team The Clinical Research Support Team (RC CRST) will be responsible for leading and coordinating the activities associated with human subjects’ research across the RC, including for example, multi-site coordination, pre-study community outreach, tracking and monitoring enrollment, recruitment, maintenance and status of regulatory documents with reporting to the CC, data collection and reporting, and compliance with human subjects’ research data and quality procedures.

The RC CRST serves as the process and procedure hub for the clinical research sites and other functional work or project areas as needed by the RC. External Advisory Committee (EAC) One External Advisory Committee for the entire CREID Network, comprised of experts in the field outside the CREID Network, will be established by NIAID after award.

The EAC will review progress of the CREID Network (including the role and progress of the RC) and share recommendations for the program with NIAID as part of the annual programmatic meeting . Note that applicants should not name EAC members in their application or contact potential EAC members until after the review is complete.

The RC will participate in one CREID Network kick-off meeting and thereafter, an annual CREID Network meeting. These meetings will serve to establish the major roles and functions of the CREID Network, facilitate collaborations, provide progress reports, seek new research directions and ideas, and update NIAID.

These meetings will be attended by the RC PD(s)/PI(s) and Key Personnel, capacity strengthening and pilot research program recipients, the EAC, the NIAID Project Scientist and other NIAID personnel, and relevant interest holders.

Applications proposing any of the following topic areas or types of research projects will be considered nonresponsive and will not be reviewed: Applications that do not focus on at least one viral pathogen on the NIAID list of Emerging Diseases . Pathogens already studied by other NIAID-funded networks, such as influenza, tuberculosis, malaria and antibiotic resistant bacteria. HIV, SIV or AIDS studies.

Genome-wide association studies (GWAS). Projects where behavioral research is the primary focus. Projects that include product development research or advancement of vaccines or antivirals.

Applications that propose a length of performance of less than 5 years in length. Clinical trials: Clinical research may be supported but not clinical trials, as defined by the NIH ( https://grants. nih.

gov/policy/clinical-trials/definition. htm ). For additional information about the Centers for Research in Emerging Infectious Diseases, see the "Frequently Asked Questions (FAQ)" link here .

See Section VIII. Other Information for award authorities and regulations. Section II.

Award Information Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.

2 for additional information about the substantial involvement for this NOFO. Application Types Allowed The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.

Not Allowed: Only accepting applications that do not propose clinical trials. Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards NIAID intends to commit $13.

5M in FY 2025 to fund 6-8 awards. Application budgets are not expected to exceed $850,000 in direct costs per year and need to reflect the actual needs of the proposed project. Project period must be 5 years in length.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. Section III.

Eligibility Information Higher Education Institutions Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education: Hispanic-serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISIs) Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Non-domestic (non-U.S.) Entities (Foreign Organizations) Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are allowed. Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award.

All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2.

3. 9. 2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually .

The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.

Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

Grants. gov – Applicants must have an active SAM registration in order to complete the Grants. gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role.

Obtaining an eRA Commons account can take up to 2 weeks. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.

Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities , NOT-OD-22-019 .

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide .

Applicants may only serve as PD/PI or be part of a multi-PD/PI team for either the Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial Not Allowed) (RFA-AI-24-006; this NOFO) or the companion Centers for Research in Emerging Infectious Diseases (CREID) Network Coordination Center (U01 Clinical Trial Not Allowed) ( RFA-AI-24-016 ), but not both .

Additionally, applicants may only serve as PD/PI or be part of a multi-PD/PI team on one (1) RC. However, the PD/PI or member of a multi-PD/PI team may serve as a collaborator on more than one RC and/or CC application. This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1.

2 Definition of Terms. 3. Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2. 3. 7.

4 Submission of Resubmission Application . This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3. 9.

4 Similar, Essentially Identical, or Identical Applications ). Section IV. Application and Submission Information 1.

Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.

gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced.

Applications that are out of compliance with these instructions may be delayed or not accepted for review. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review. By the date listed in Part 1.

Overview Information , prospective applicants are asked to submit a letter of intent that includes the following information: Descriptive title of proposed activity Name(s), address(es), and telephone number(s) of the PD(s)/PI(s) Names of other key personnel Participating institution(s) Number and title of this funding opportunity The letter of intent should be sent to: All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed, with the following additional instructions: For this specific NOFO, the Research Strategy is limited to 30 pages.

Instructions for Application Submission The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO. All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply - Application Guide must be followed.

SF424(R&R) Other Project Information All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Facilities and Other Resources: Provide the following information in the Facilities and Other Resources attachment.

Use separate sections to differentiate the requested information as indicated below: Within a section titled, "Information Technology Access and Resources,” briefly describe the features of the institutional environment that are relevant to the implementation of the proposed collaborations and/or research sites within the RC.

Describe available Informational Technology (IT) resources with respect to access to computers, source and status of reliable, secure internet connections, and other communications. Within a section titled, "Biological Specimen Storage and Access,” briefly describe the facilities available to securely store, manage, and retrieve biological specimens for use by the PD/PI(s) and Key Personnel in the research projects.

SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Within the Biosketch of the PD(s)/PI(s), under Personal Statement, describe the leadership approach and experience of the PD(s)/PI(s) with respect to developing and implementing multi- or interdisciplinary research program(s) of a similar size and nature, including multi-site/partner consortiums with domestic and/or international entities.

Within the Biosketch of each Key Personnel, under Personal Statement, describe the administrative, technical, and management expertise in areas critical to the success of the application, including experience working productively in collaborative team environments, and the scientific expertise and experience working in geographic regions proposed.

Demonstrate how specific expertise supports the multi- and/or interdisciplinary approach to guarantee a successful, integrated effort towards the goals of the research project.

All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Within the relevant budget sections, include the following: Enter the ‘person months effort’ for the PD(s)/PI(s) and Key Personnel in the budget section based on the allocation of their respective roles on the project.

CREID Network Kick-Off Meeting: In Year 01, include funds for the RC PD(s)/PI(s) and Key Personnel to travel and attend a CREID Network kick-off meeting hosted by NIAID. The kickoff meeting will be held over 1 full day in the greater Washington, DC metro area.

Annual CREID Network meetings: In Year 02, 03 and 04, include funds for the RC PD(s)/PI(s) and Key Personnel to travel and attend the annual CREID Network meetings to be held over 3 full days in an international location. In Year 05, include funds for the RC PD(s)/PI(s) and Key Personnel to travel and attend the annual CREID Network meeting to be held over 3 full days in the greater Washington, DC metro area.

Specimens: Include costs associated with biological specimen collection, processing, shipping, and storage as well as costs for depositing reagents and tools to NIAID-supported repositories (see listing of repositories here: https://www. niaid. nih.

gov/research/resources ). Opportunity Fund: Applicants are expected to budget $100,000 each year in direct costs for this fund. All instructions in the How to Apply - Application Guide must be followed.

PHS 398 Cover Page Supplement All instructions in the How to Apply - Application Guide must be followed. All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Specific Aims: List in priority order, the broad, long-range objectives and goals of the proposed research and indicate how these goals will be accomplished.

Concisely describe the hypothesis or hypotheses to be tested and plans for incorporation of other emerging or re-emerging infectious disease pathogens, as needed. Describe the overall One Health strategy, procedures and approaches used to accomplish the RC research objectives and goals. Describe and justify the choice of targeted pathogen(s)/disease(s) to address the most relevant viral emerging pathogens.

Describe how the outcomes from individual research activities are integrated into the aims of the RC. Discuss how the RC proposed research plans, procedures and approaches may be leveraged to address specific emerging/re-emerging disease outbreaks. Describe the rationale for the geographical regions in which the RC will operate.

Describe how and to what extent the research and activities will be coordinated and synergized within the RC ensure achievement of its central objectives. In a clearly labeled section entitled “Administrative Plan”: Describe the role of the RC ALT in oversight and management of the administrative plan.

Describe the plan for overall administration of the RC, including the organizational structure, governance, staffing plan, lines of authority, the process for tracking and monitoring progress, the fiscal management plan, and other administrative procedures to ensure progress in meeting the goals and objectives of the RC.

Describe the communication plan for the RC, including the various methods for bidirectional and unidirectional communications within the RC Teams (ALT, DSAT, CRST), across the like-named Network Teams (e.g., RC ALT with CC ALT), and broadly to all staff of the RC. As part of this plan, describe the plans for communicating with the CREID Network, NIAID, and relevant interest holders.

Describe how the RC will manage their domestic and international research sites. Describe the plans for collaboration, cooperation, and coordination with all CREID RCs and CC. Discuss the overall process, including how the management, oversight, and assigned responsibilities will be planned, articulated, implemented, and monitored for progress of a shared goal.

In a clearly labeled section entitled "Data Stewardship and Analysis Plan” applicants should address the range of data stewardship and analysis activities within the RC related to data and information generated by the RC and exchanged amongst the CREID Network award recipients (RC and CC) Specifically: Describe the role and approach of the RC DSAT in